In a new study from South Korea, researchers explored a novel therapy for nocturia (awakening to urinate at night). The researchers noted that traditional therapies, including alpha-blocking medications such as tamsulosin, terazosin, and doxazosin, do a poor job of improving this specific symptom. These medications work to relax the muscles of the prostate to maximize your ability to empty your bladder.
These researchers theorized that nocturia is caused by multiple factors -- not just urinary retention. Therefore, by adding desmopressin they attempted to decrease the amount of urine produced each night. Results were successful, but the greatest improvement was found in men under age 65. Furthermore, the greatest side effects, including dangerously-low sodium, in men over age 65.
While not currently FDA approved for nocturia, these therapy offers a novel approach specifically tailored to this symptom. Currently approved for therapy in diabetes insipidus, consideration of this therapy has merit for patients lacking improvement with historical therapies.